Maple Capital Management Inc. decreased its position in shares of Cerner Co. (NASDAQ:CERN) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,450 shares of the company’s stock after selling 1,151 shares during the quarter. Maple Capital Management Inc.’s holdings in Cerner were worth $974,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Cerner by 2.2% in the 4th quarter. BlackRock Inc. now owns 19,519,304 shares of the company’s stock worth $1,315,406,000 after buying an additional 420,942 shares during the last quarter. Capital International Investors lifted its position in shares of Cerner by 0.3% during the third quarter. Capital International Investors now owns 4,851,296 shares of the company’s stock worth $345,994,000 after acquiring an additional 12,178 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Cerner by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 3,759,894 shares of the company’s stock worth $252,916,000 after acquiring an additional 98,444 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Cerner by 3.7% during the fourth quarter. American Century Companies Inc. now owns 3,204,461 shares of the company’s stock worth $215,949,000 after acquiring an additional 114,224 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Cerner by 1.8% in the third quarter. Legal & General Group Plc now owns 1,477,451 shares of the company’s stock worth $105,371,000 after purchasing an additional 25,842 shares during the period. 78.54% of the stock is currently owned by institutional investors.
Cerner Co. (NASDAQ:CERN) traded down $0.15 during mid-day trading on Friday, reaching $57.32. 603,675 shares of the company traded hands, compared to its average volume of 2,544,321. The company has a current ratio of 3.01, a quick ratio of 2.99 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $19,909.28, a price-to-earnings ratio of 22.30, a PEG ratio of 1.74 and a beta of 0.93. Cerner Co. has a 52 week low of $56.51 and a 52 week high of $73.86.
Cerner (NASDAQ:CERN) last released its quarterly earnings data on Tuesday, February 6th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by ($0.03). Cerner had a return on equity of 16.82% and a net margin of 16.86%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the previous year, the business posted $0.61 earnings per share. Cerner’s revenue for the quarter was up 4.5% on a year-over-year basis. research analysts predict that Cerner Co. will post 2.42 EPS for the current year.
In other news, Vice Chairman Clifford W. Illig sold 307,700 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $64.52, for a total transaction of $19,852,804.00. Following the completion of the sale, the insider now owns 1,229,719 shares in the company, valued at approximately $79,341,469.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William D. Zollars sold 4,100 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $62.16, for a total transaction of $254,856.00. The disclosure for this sale can be found here. Insiders sold 541,800 shares of company stock valued at $34,353,860 in the last 90 days. Company insiders own 13.11% of the company’s stock.
A number of research firms recently commented on CERN. Zacks Investment Research raised Cerner from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. BidaskClub lowered shares of Cerner from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $80.00 price objective on shares of Cerner in a report on Monday, March 5th. Evercore ISI started coverage on shares of Cerner in a research report on Thursday, January 18th. They issued an “in-line” rating and a $77.00 target price for the company. Finally, SunTrust Banks dropped their price target on shares of Cerner from $68.00 to $2.82 and set a “hold” rating on the stock in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $67.50.
WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/03/23/cerner-co-cern-shares-sold-by-maple-capital-management-inc.html.
Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations of all sizes. The Company’s segments include Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States.
Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.